Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

@article{Brand2011ErlotinibIA,
  title={Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab},
  author={T. Brand and E. F. Dunn and M. Iida and R. Myers and Kellie T. Kostopoulos and C. Li and Chimera R. Peet and D. L. Wheeler},
  journal={Cancer Biology & Therapy},
  year={2011},
  volume={12},
  pages={436 - 446}
}
  • T. Brand, E. F. Dunn, +5 authors D. L. Wheeler
  • Published 2011
  • Medicine
  • Cancer Biology & Therapy
    • The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab, and cetuximab) and three tyrosine kinase inhibitors (erlotinib, gefitinib, and lapatinib). Both strategies of EGFR inhibition have demonstrated clinical successes, however many tumors remain non-responsive or acquire… CONTINUE READING
    View on Taylor & Francis
    tandfonline.com
    15 Citations
    Background Citations
    9
    Methods Citations
    1
    Results Citations
    3
    15 Citations
    Citation Type

    Citation Type

    Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    • 44
    Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
    • 55
    AXL mediates resistance to cetuximab therapy.
    • 122
    • PDF
    Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
    • 20
    • PDF
    Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer
    • 29
    Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol
    • 10
    • PDF
    Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung Cancer
    • PDF
    Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    • 15
    • PDF
    Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.
    • 2
    Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
    • 59
    • PDF

    References

    SHOWING 1-10 OF 58 REFERENCES
    Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
    • 486
    • PDF
    Nuclear EGFR contributes to acquired resistance to cetuximab
    • 265
    • PDF
    Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
    • 141
    Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
    • 370
    • PDF
    Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    • A. Bardelli, S. Siena
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 606
    Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells
    • 91
    • PDF
    Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
    • 150
    • PDF
    Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    • 218
    • PDF
    Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
    • 295
    • PDF
    EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    • 140